TREAT-B has Good Accuracy in Selecting HBV Infected Patients for Treatment in Sudan

Elhasan, Mogahid Mahmoud and Kheir, Omer Osman and Patwa, Yashwi Haresh and Bakhit, Aya Tarig and Abdalla, Hala Ibrahim (2022) TREAT-B has Good Accuracy in Selecting HBV Infected Patients for Treatment in Sudan. Asian Journal of Medicine and Health, 20 (12). pp. 204-211. ISSN 2456-8414

[thumbnail of 784-Article Text-1390-1-10-20230107.pdf] Text
784-Article Text-1390-1-10-20230107.pdf - Published Version

Download (303kB)

Abstract

Non-invasive and invasive diagnostic methods, which are not readily available in Sudan, are used to guide HBV treatment. Africa adopted the TREAT-B as a straightforward score in 2018 to identify patients in need of anti-HBV treatment.

Objective: To compare the diagnostic accuracy of the TREAT-B score to the standard scores EASL and AASLD in HBV patients.

Methods: At Ibn Sina Specialized Hospital, 108 HBV patients were enrolled in an analytical cross-sectional study (January- October 2019). Data was collected using an interviewer-administered questionnaire and analyzed using SPSS.

Results: Eight patients (7.4%) were eligible for therapy under the AASLD recommendations, 18 patients (16.7%) were suitable under the EASL guidelines, and twenty-seven patients (25%) were eligible under the TREAT-B guidelines. According to the Wald statistic, the AUROC of TREAT-B (0.883; 95% CI 0.790-0.976; Sen. 85.3%; Sp. 70.3%) was substantially higher than the AUROC of the AASLD criteria (0.722; 95% CI 0. 0.566-0.878; Sen. 74.4%; Sp. 69.8%); and lower than the AUROC of the EASL criteria (0.952; 95% CI 0.790-0.976.

Conclusion: The TREAT-B score was effective at identifying HBV-infected patients who should receive antiviral treatment.

Item Type: Article
Subjects: European Repository > Medical Science
Depositing User: Managing Editor
Date Deposited: 10 Jan 2023 06:55
Last Modified: 31 Jan 2024 03:52
URI: http://go7publish.com/id/eprint/1821

Actions (login required)

View Item
View Item